Immunic, Inc.

Stocks

IMUX

US4525EP2001

Real-time Estimate Cboe BZX 12:08:16 2026-11-13 EST			5-day change	1st Jan Change
7.825 ^USD	+0.45%		0.00%	+45.21%

11-05	Immunic, Inc. - Special Call
10-23	Cantor Fitzgerald Initiates Coverage on Immunic With Overweight Rating	MT

Transcript : Immunic, Inc. - Special Call

Published on 11/05/2026 at 03:05 pm EST - Modified on 11/09/2026 at 08:05 pm EST

S&P Capital IQ

Presenter Speech
Jessica Breu (Executives)

Hello, and welcome to Immunic's Virtual R&D Day focusing on our Progressive MS development program with our investigational asset, Vidofludimus Calcium. I

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Immunic, Inc.

11-05	Immunic, Inc. - Special Call
10-23	Cantor Fitzgerald Initiates Coverage on Immunic With Overweight Rating	MT
10-21	Immunic, Inc. Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations At Mstoronto2026	CI
10-19	Immunic, Inc. Announces Appointment of Jaa Roberson as Chief People Officer, Effective October 19, 2026	CI
10-07	Immunic, Inc. Presents New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium At Mstoronto2026	CI
09-11	Immunic, Inc. Announces Resignation of Duane Nash as Member of the Board of Directors	CI
09-09	Immunic, Inc. - Special Call
09-01	Roth Capital Partners Adjusts Price Target on Immunic to $29 From $19, Maintains Buy Rating	MT
09-01	Immunic, Inc. Announces Appointment of Chitrang Davé to Chief Data and Digital Officer, Effective September 1, 2026	CI
08-17	Wedbush Initiates Immunic at Outperform With $45 Price Target	MT
08-11	Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Immunic, Inc. Announces Appointment of Elena Ridloff to Board of Directors, Effective August 6, 2026	CI
07-06	Immunic, Inc. Announces Board and Committee Changes	CI
06-29	Immunic, Inc.(NasdaqCM:IMUX) added to Russell Microcap Value Benchmark Index	CI
06-28	Immunic, Inc.(NasdaqCM:IMUX) added to Russell 3000E Value Benchmark	CI

Chart Immunic, Inc.

Duration

Period

IMUX: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Immunic, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Immunic, Inc.

Revisions to estimates